331 results on '"McKone E"'
Search Results
2. WS06.03 Efficacy and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in people with cystic fibrosis and ELX/TEZ/IVA-responsive, non-F508del genotypes: a phase 3, randomised, placebo-controlled trial
3. P412 “Should I stay or should I go now?” (Transitioning to CF Adult Care)
4. P057 Measuring adherence to chronic therapies over the first year of treatment with elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (CF) aged 6–11 years – the RECOVER study
5. EPS4.01 Impact of 18 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with CF – the RECOVER study
6. WS04.05 Sustained improvement in abdominal symptoms measured by the CFAbd-Score over 2 years of treatment with elexacaftor/tezacaftor/ivacaftor in people with CF aged ≥12 years: results from the RECOVER study
7. EPS4.02 Exploring barriers to treatment adherence in people with cystic fibrosis: insights from the RECOVER study at 24 months
8. P078 Hyperacute response to cystic fibrosis transmembrane conductance regulator modulation
9. Thymic neoplasms treated with intensity modulated proton therapy
10. 485 Measuring adherence to chronic therapies over 2 years of treatment with elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis—the RECOVER Study
11. 547 Reduction in abdominal symptoms measured by Cystic Fibrosis Abdomen-score over 6 months of treatment with elexacaftortezacaftor-ivacaftor in children with cystic fibrosis aged 6 to 11: early results from the RECOVER study
12. 83 Evaluation of ivacaftor and antibiotic therapies on breath biomarkers for Pseudomonas aeruginosa and Staphylococcus aureus in cystic fibrosis
13. 142 Elexacaftor-tezacaftor-ivacaftor and spirometry-controlled chest CT scores in children with cystic fibrosis aged 6 to 11
14. 196 Airway infection and inflammation in people with cystic fibrosis treated with 1 year of elexacaftor-tezacaftor-ivacaftor—the RECOVER study
15. 144 Changes in airway nitric oxide in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor—Results from the RECOVER study
16. 138 Clinical outcomes in people with cystic fibrosis after 2 years of elexacaftor-tezacaftor-ivacaftor: Results from the RECOVER study
17. EPS6.05 A phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity in people with cystic fibrosis (CF)
18. P044 Oral and intravenous antibiotic requirements prior to and following elexacaftor/tezacaftor/ivacaftor treatment in children and adults with cystic fibrosis – analysis from the RECOVER Study
19. WS05.03 A phase 3b study of the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on glucose tolerance in people with cystic fibrosis (CF) and abnormal glucose metabolism
20. 158 Longitudinal profiles of human breath reveal potential biomarkers for detecting and monitoring infections in cystic fibrosis during ivacaftor and antibiotic therapy.
21. 166 Measuring adherence to chronic therapies over the first year of treatment with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis
22. 156 Multicenter validation of the CF-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis
23. 170 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from an open-label extension study
24. 251 Evaluation of the Medication Electronic Monitoring Systems n adherence measurement in a real-world setting
25. 185 Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for F508del-CFTR and a gating or residual function mutation
26. Rate of lung function decline in patients with cystic fibrosis (cf) having a residual function gene mutation: P255
27. P043 Significant reduction in abdominal symptoms assessed with the CFAbd-Score over 6 months of elexacaftor/tezacaftor/ivacaftor (ETI) - follow-up results from Irish and British cystic fibrosis patients (RECOVER study)
28. ePS6.10 A real-world study evaluating the impact of elexacaftor/tezacaftor/ivacaftor treatment on medication adherence in cystic fibrosis
29. WS06.02 Impact of one year of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in people with cystic fibrosis in a real-world setting – the RECOVER study
30. 564: Impact of elexacaftor/tezacaftor/ivacaftor treatment on clinical outcomes in people with CF in a real-world setting—The RECOVER trial
31. 565: Significant reduction in abdominal symptoms assessed with CFAbd score over 4 weeks of treatment with elexacaftor/tezacaftor/ivacaftor—First results from the RECOVER study
32. Recall of provision of sun protection advice to patients with cystic fibrosis taking voriconazole: PD13
33. P127 Twenty years and counting: longitudinal trends in real-world primary outcomes for people with cystic fibrosis in Ireland and the evolution of a registry
34. P038 Direct measurement of short-term adherence to elexacaftor/tezacaftor/ivacaftor and changes in sweat chloride levels – results from the RECOVER Study
35. P005 An audit on adherence to guidelines on screening colonoscopies in an adult cystic fibrosis centre
36. EPS6.07 Longitudinal impact of elexacaftor/tezacaftor/ivacaftor on abdominal symptoms assessed with the CFAbd-Score and on intestinal inflammation in people with cystic fibrosis aged ≥ 12 years – The RECOVER study
37. EPS6.06 Impact of 6 months of treatment with elexacaftor/tezacaftor/ivacaftor on clinical outcomes in children aged 6–11 with cystic fibrosis – The RECOVER study
38. EPS6.02 Elexacaftor/tezacaftor/ivacaftor results in substantial improvements in chest CT scores in people with cystic fibrosis aged 12 and above over one year of treatment
39. P042 RECOVER - the Real World Clinical Outcomes with Novel Modulator therapy combinations in people with cystic fibrosis
40. P083 Clinical progression of SARS-CoV-2 infection in people with cystic fibrosis: a global observational study
41. P156 Mycobacterium abscessus treatment in adult patients with cystic fibrosis: case series and review
42. P071 Real-world pregnancy data and outcomes in an era post-CFTR modulation therapies: an Irish centre's perspective
43. Lemierre’s syndrome
44. LONG-TERM SAFETY AND EFFICACY OF IVACAFTOR IN PERSONS WITH CYSTIC FIBROSIS WHO HAVE THE G551D-CFTR MUTATION: 211
45. LONG-TERM SAFETY AND EFFICACY OF INVESTIGATIONAL CFTR POTENTIATOR, VX-770, IN SUBJECTS WITH CF: 204
46. Lemierre's syndrome
47. P102 Mycobacterium abscessus treatment complexity in adult patients with cystic fibrosis: case series and review
48. ePS3.02 Increased extracellular vesicles mediate inflammatory signalling in cystic fibrosis
49. P267 An evaluation of the nutritional status of Irish adults attending the National Referral Centre for Adult Cystic Fibrosis in 2019
50. Do people have insight into their face recognition abilities?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.